- Vinod A Chaure, Saurabh B Ganorkar, Sanjay J Surana and Atul A Shirkhedkar, R. C. Patel, Institute of Pharmaceutical Education and Research, Shirpur, Dist: Dhule (MS) India 425 405
- Ganesh U Chaturbhuj, Institute of Chemical Technology, ICT, Matunga, Mumbai 400019
Tenofovir Disoproxil Fumarate, Review Article, Validation, HPLC, HPTLC
Tenofovir Disoproxil Fumarate (TDF) is antiretroviral medicine used treat AIDS as well as chronic Hepatitis-B. TDF is a prodrug of tenofovir and exists as dominant form due to lesser oral bioavailability of parent drug. TDF is now available in a fixed-dose combination with various antiretrovirals like Cobicistat, Efavirenz, Elvitegravir, Emtricitabine, Lamivudine, Rilpivirine, and Nevirapine. Hence, pharmaceutical analysis of TDF and applicability of different analytical methods have gained crucial importance. The present review article assesses the published analytical methods and a variety of approach for investigation of TDF in bulk drug as well as pharmaceutical formulations including combinations…
Goicoechea M., Liu S., Best B., Sun S., Jain S., Kemper C., Witt M., Diamond C., Haubrich R. and Louie S. (2008). Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy, J. Infectious Diseases, 197(1), 102–108. https://doi.org/10.1086/524061
Avihingsanon A., Sophonphan J., Thammajaruk N., Chaihong P., Burger D., Cressey T. R., Ramautarsing R. A., Praditornsilpa K., Avihingsanon Y., Ruxrungtham K. and HIV-NAT 114 study team. (2015). Plasma Tenofovir Concentrations and Proximal Tubular Dysfunction in HIV-Infected Adults Receiving Tenofovir in Thailand, J. AIDS & Clinical Research, 6(7), 477. https://doi.org/10.4172/2155-6113.1000477
Patel K. K., Patel A. K., Ranjan R. R., Patel A. R. and Patel J. K. (2010). Tenofovir-associated renal dysfunction in clinical practice: An observational cohort from western India, Indian J. STD and AIDS, 31(1), 30–34. https://doi.org/10.4103/0253-7184.68998
Bygrave H., Ford N., van C. G., Hilderbrand K., Jouquet G., Goemaere E., Vlahakis N., Trivino L., Makakole L. and Kranzer K. (2011). Implementing a tenofovir-based first-line regimen in rural Lesotho: clinical outcomes and toxicities after two years, J. AIDS, 56(3), e75-e78. https://doi.org/10.1097/QAI.0b013e3182097505
The Merck Index, 13 TH Editions, Merck Research Laboratories, Merck and CO., White House Station, NJ, USA, 2001, 1631–1632.
Kearney B. P., Flaherty J. F. and Shah J.: Tenofovir disoproxil fumarate, Clinical Pharmacokinetics, 2004, 43(9), 595–612. https://doi.org/10.2165/00003088-200443090-00003
James C. W., Steinhaus M. C., Szabo S. and Dressler R. M. (2004). Tenofovir‐related nephrotoxicity: case report and review of the literature. Pharmacotherapy, The Journal of Human Pharmacology and Drug Therapy, 24(3), 415–418. https://doi.org/10.1592/phco.24.4.415.33182
www.Gilead.com/pdf/viread_pi.pdf; Gilead Science Inc. Viread, US prescribing information.